2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 15: November 29, 2023 - Atopic Dermatitis Guideline Update and What You Need to Know Now about STDs
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, November 29, 2023
8 PM ET / 5 PM PT
New Guidelines of Care for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies, and What You Need to Know NOW About STDs
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 30, 2023
November 30, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Appreciate the widespread prevalence and current epidemiology of syphilis
Integrate new FDA approved treatment for scabies, as needed
To review the current systemic therapies from the American academy of dermatology’s newly published guidelines of care for atopic dermatitis
To review assessments of severity for choosing systemic therapies or phototherapy
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
David Cohen, MD, MPH
Charles C. and Dorothea E. Harris Professor
Vice Chairman for Clinical Affairs
New York University School of Medicine
New York, NY
Theodore Rosen, MD
Professor of Dermatology
Baylor College of Medicine
Chief of the VA Dermatology Service
VA Medical Center
Houston, TX
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: ASLAN, Almirall, Amgen, Arcutis, Beiersdorf, BMS, Dermavant, EPI
Health, Janssen, LEO Pharma, Mindera, Nimbus, Organon & Co, Sanofi, SUN Pharma, Takeda, Ventyx Biosciences
Board Member: Board of Director Elect, American Academy of Dermatology
Grant/Research Support: Abbvie, ASLAN, Bristol Myers Squibb, Dermavant Sciences, Dermira, Eli
Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Seika Pharma Co, Modernizing Medicine, Nimbus Therapeautics, Novartis, Ortho Dermatologics,
Pfizer, Sanofi, Genzyme, UCB, Ventyx Biosciences
Speakers Bureau: Abbvie, Amgen, BMS, Janssen, Mindera, Organon & Co, Sanofi, Takeda
Other Relationships: Data Safety Monitoring Board: Boehringer Ingelheim, Parexel
Advisory Board/Consultant: Ferndale, Medimetriks, Leo, UCB, Novartis [past], SFJ [past], FIDE, Cosmetic Ingredient Review
Board Member: Board of Directors: Kadmon [past], Timber, Evommune
Shareholder: Kadmon [past], Evommune, Timber
Advisory Board: Verrica Pharmaceuticals
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.